Donna has over twenty-five years’ experience in corporate public affairs management and public policy. Trading as Astute Advocacy, Donna is delighted to collaborate with Shawview. She provides a range of services to improve business value for health leaders including government relations advice, stakeholder engagement plans and campaigns, strategic policy and corporate affairs advice, executive coaching, association management support, and she produces a weekly political bulletin. Prior roles include head of Public Affairs for Medicines Australia, COO and Company Secretary for both the National Pharmaceutical Services Association and the Hearing Care Industry Association, manager of government relations for Australia’s premier science agency the CSIRO, and federal government relations for an airline in Australia. She was policy director in the Department of the Prime Minister & Cabinet and worked within a Cabinet Minister’s office. Donna holds a BSocSc (Hons) from UNSW, is a graduate of the Australian Institute of Company Directors and is a long-time member of the National Press Club of Australia.

Andrew Jenner is Executive Director of Jenner Strategic Consulting offering offers experienced public affairs and business consultancy services. Before forming Jenner Strategic Consulting in 2014 based in the UK, Andrew was Executive Director of Corporate Strategy & Legal Affairs at the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in Geneva. Prior to this Andrew was Head of Trade and Development for the UK Government’s Intellectual Property Office (IPO), where he led the UK Government delegation to the World Trade Organization and the World Intellectual Property Organization, as well as being the principal EU negotiator on the World Health Organization’s negotiations on Public Health, Innovation and IP. Andrew holds a Bachelor of Engineering degree with honours, a Diploma in Law and Intellectual Property and Master of Laws from the University of Wales.

Unjela has extensive global experience in leadership roles in Public Affairs and Communications in diverse organizations such as Nestle, UN Office of Project Services (UNOPS), The World Bank, International Federation of Pharmaceutical Manufacturer & Association (IFPMA), Overseas Investors Chamber (OICCI), Dow Jones, British Broadcasting Corporation. Based in Geneva, she has had a career spread over 20 years across Oceania, Europe, Africa, MENA , and Asia. Unjela has extensive experience in helping organizations optimise their value proposition through the development and implementation of ESG and purpose focused communications & advocacy strategies. She is skilled in team development, has significant experience in crisis and media management and is highly adept in public speaking, Unjela has managed small and large multicultural teams and led high-level international delegations, served on company boards, leadership teams and publicly represented organisations as a spokesperson. Unjela has a double Masters in Mass Communication and Gender Studies from SOAS, University of London. She was also the first female CEO of an international chamber of commerce in Asia.

Evan Lee is a Geneva-based consultant and an expert in global health policy. He has previously worked for pharmaceutical company Eli Lilly as Vice President Global Health and Programs, the Senior Adviser to Foundation for Innovative New Diagnostics (FIND), a consultant with Management Sciences for Health and Medical Coordinator with Medicines Sans Frontieres. He has worked on many global health and access to medicines issues including diabetes, cardiovascular disease in low- and middle-income countries, public affairs and business strategy. A medically qualified doctor by training, he has a BA in chemistry and physics from Harvard University, a medical degree from New York University School of Medicine and an MBA from Massachusetts Institute of Technology.

Jorge Mestre-Ferrandiz is an independent economics consultant, based in Madrid, Spain, having spent 15 years at The Office of Health Economics with various positions including as an Industrial Economist and as Director of Consulting. Jorge has over 15 years’ experience consulting to the pharmaceutical industry and related non-profit organisations and his clients have included a number of global top 30 pharmaceutical companies and a range of NGOs. He specialises in the economics of the industry, the pricing and reimbursement of medicines, the impact of public policy on innovation, market access, the economics of antimicrobial resistance (AMR), and pharmaceutical product portfolios. Jorge has a PhD in Economic Analysis from the University Autonoma of Barcelona, has published over 50 papers on health economics and is regularly invited to speak on related topics at academic and commercial international conferences. He is a Visiting Fellow at OHE, Director, Oxford Martin Programme on Affordable Medicines, Oxford Martin School, University of Oxford, an Honorary Visiting Lecturer at the Department of Economics, City University London, and Health Economics Professor at Instituto de Empresa (IE) Business School, Madrid.

Siddhartha has extensive experience in health systems, pharmaceutical policy, intellectual property, pricing, reimbursement, innovative business models and access to medicines. Siddhartha has worked with international organisations such as the World Trade Organization, World Health Organization and the World Bank as well as several international pharmaceutical companies, device companies and consulting firms. Siddhartha has over 20 years of experience working in emerging markets in Asia and Africa on public private partnerships and facilitating cross-sectoral dialogue on policy options and access strategies. He holds a degree in geography from University College London and a masters in the economic history of developing countries from the London School of Economics.

Rob has over 20 years’ experience advising health and medical technology companies on market entry, M&A, business planning, investment and venture capital raising in the Chinese health market. He has previously worked in related senior roles for EY, Austrade and the Queensland state government. For the last 10 years, Rob has run an advisory business based in Shanghai for life sciences and medical technology companies seeking to enter China and Chinese investment funds. Rob has worked with clients to navigate the complex and evolving Chinese life sciences market and regulatory landscape. He advises in market entry; due diligence; partner development; distribution, contract and licence negotiation; commercialisation; clinical trial and regulatory support. Rob is a member of the Australian Institute of Company Directors and formerly Executive Director of the Australia-China Business Council. He holds an MBA from Griffith University and a Master of Public Health from the Queensland University of Technology.

Sunayana Shah is an expert in regulatory, scientific, medical, pharmacovigilance policy and issues at national and international level. Based in London, she has extensive experience in complex stakeholder management, policy analysis and communication, particularly in complex technical scientific areas. Sunayana previously was Head of Regulatory and Safety Policy at the Association of the British Pharmaceutical Industry (ABPI) where she advised the pharmaceutical industry and worked with UK, European and international agencies on international regulatory policy issues, including Brexit. Previously, she led scientific and medical affairs at the Proprietary Association of Great Britain (PAGB) leading on national and international OTC policy, regulatory issues and professional programs. She has also been Senior Staff editor of the British National Formulary, Royal Pharmaceutical Society and has extensive community pharmacy experience. Sunayana holds an honours degree from the School of Pharmacy, University of London, and Post Graduate Diplomas in Evidence based Pharmacotherapy (Aston University) and Community Pharmacy (University of Keele). She is a GPhC registered pharmacist and a Fellow and Ambassador of the Royal Pharmaceutical Society.

Chris Strutt has over 30 years’ experience as an adviser and strategist in government affairs and public policy. Now a consultant, Chris was most recently Senior Vice-President (SVP) and Special Adviser to the CEO and Corporate Executive Team at global pharmaceutical company GSK. He previously held various senior government affairs and public policy positions at GSK, and prior to this worked in consultancy and in senior policy positions in the UK Government. Chris’ substantial experience ranges across a wide range of issues, stakeholders and geographies, and his expertise includes political strategy, risk assessment, policy analysis, and reputation and crisis management. Chris has an honours degree in History from Cambridge University.

Brendan Warr is Senior Associate Consultant with Shawview Consulting. Based in Canberra, Brendan supports multiple policy, public affairs and economic projects. He has previously worked in the Federal Secretariat of Australia’s Liberal Party, including on its 2022 Federal Election Campaign team, supporting Liberal Members of Parliament and candidates during the campaign, as well as running training and development programs for new Liberal Party MPs and their electorate offices around Australia. Previously, Brendan worked for two years as Policy Advisor and Electorate Officer to the Leader of the Opposition in the Australian Capital Territory Legislative Assembly. He has completed internships with Senators in the Australian Senate and worked in the retail sector for several years. Brendan holds a Bachelor of Politics, Philiosophy and Economics from the Australian National University in Canberra.

Kangping (Bill) Zhou is an Intern with Shawview Consulting. Based in Sydney, Bill undertakes a variety of policy and research projects on topics such as global health policy, regulatory policy, medicines, clinical trials, genomics and Chinese health and pharmaceutical policy. He is in his third year of a Bachelor of Science (Medical Science) at the University of Sydney.